Long-term imatinib therapy promotes bone formation in CML patients

Blood

Volumn 111, Issue 5, 2008, Pages 2538-2547

  Fitter, Stephen ^a   Dewar, Andrea L ^a   Kostakis, Panagiota ^a   To, L Bik ^b   Hughes, Timothy P ^b   Roberts, Marion M ^b   Lynch, Kevin ^c   Vernon Roberts, Barrie ^d   Zannettino, Andrew C W ^a,d  

^a Bone and Cancer Research Laboratories   (Australia)

^b HANSON INSTITUTE   (Australia)

^c Medical Oncology   (Australia)

^d INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CRK LIKE PROTEIN; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; CALCIUM; ONCOPROTEIN; PHOSPHATE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHOSPHATEMIA; ILIAC CREST; LONG TERM CARE; MALE; OSTEOBLAST; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; TRABECULAR BONE; ADIPOGENESIS; BLOOD; BONE DEVELOPMENT; BONE MINERALIZATION; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STEM CELL; METABOLISM; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; TIME;

ADIPOGENESIS; ADULT; AGED; ANTINEOPLASTIC AGENTS; CALCIFICATION, PHYSIOLOGIC; CALCIUM; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; ORGAN SIZE; OSTEOGENESIS; PHOSPHATES; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-CRK; PYRIMIDINES; TIME FACTORS;

EID: 41949120243     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-07-104281     Document Type: Article

References (56)

1. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
2. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
3. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005; 105:3127-3132.
4. Tanaka S, Takahashi N, Udagawa N, et al. Mac- rophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest. 1993;91: 257-263.
5. Dewar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006;107:4334-4337.
6. Grigoriadis AE, Heersche JN, Aubin JE. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. J Cell Biol. 1988;106:2139-2151.
7. Grigoriadis AE, Heersche JN, Aubin JE. Continuously growing bipotential and monopotential myo- genic, adipogenic, and chondrogenic subclones isolated from the multipotential RCJ 3.1 clonal cell line. Dev Biol. 1990;142:313-318.
8. Yamaguchi A, Kahn AJ. Clonal osteogenic cell lines express myogenic and adipocytic developmental potential. Calcif Tissue Int. 1991;49:221-225.
9. Hock JM, Canalis E. Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology. 1994;134:1423-1428.
10. Kubota K, Sakikawa C, Katsumata M, Nakamura T, Wakabayashi K. Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res. 2002;17:257-265.
11. Chaudhary LR, Hofmeister AM, Hruska KA. Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone. 2004;34:402-411.
12. Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, Hicklin DJ. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone. 1994;15:203-208.
13. Mitlak BH, Finkelman RD, Hill EL, et al. The effect of systemically administered PDGF-BB on the rodent skeleton. J Bone Miner Res. 1996;11:238-247.
14. Li B, Boast S, de los Santos K, et al. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat Genet. 2000;24:304-308.
15. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354: 2006-2013.
16. Grey A, O'Sullivan S, Reid IR, Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med. 2006;355:2494-2495.
17. Revell PA. Quantitative methods in bone biopsy examination. In: Revell PA, ed. Pathology of Bone. Berlin: Springer-Verlag; 1986:87-111.
18. Melsen F, Melsen B, Mosekilde L, Bergmann S. Histomorphometric analysis of normal bone from the iliac crest. Acta Pathol Microbiol Scand [A]. 1978;86:70-81.
19. Gundle R, Stewart K, Screen J, Beresford JN. Isolation and culture of human bone-derived cells. In: Beresford JN, Owen ME, eds. Marrow Stromal Cell Culture. Cambridge: Cambrige University Press; 1998:43-66.
20. Gronthos S, Zannettino AC, Graves SE, Ohta S, Hay SJ, Simmons PJ. Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J Bone Miner Res. 1999;14:47-56.
21. Jaiswal RK, Jaiswal N, Bruder SP, Mbalaviele G, Marshak DR, Pittenger MF. Adulthuman mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated bymitogen-activated protein kinase. J Biol Chem. 2000;275:9645-9652.
22. Frydecka I, Bieniek J, BrodzkaW. Osteolytic lesion in chronic myelogenous leukaemia. Folia Haematol Int Mag Klin Morphol Blutforsch. 1984; 111:610-613.
23. Thiele J, Hoeppner B, Wienhold S, Schneider G, Fischer R, Zankovich R. Osteoclasts and bone remodeling in chronic myeloproliferative disorders. Ahistochemical and morphometric studyon trephine biopsies in 165 patients. Pathol Res Pract. 1989;184:591-599.
24. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
25. le Coutre P, Kreuzer KA, Pursche S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol. 2004;53:313-323.
26. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994;171:131-137.
27. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified, culture- expanded human mesenchymal stem cells in vitro. J Cell Biochem. 1997;64:295-312.
28. Sattler M, Salgia R, Okuda K, et al. The proto- oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996;12:839-846.
29. Moore RJ, Durbridge TC, Woods AE, Vernon- Roberts B. Comparison of two bone trephine instruments used for quantitative histomorphometry. J Clin Pathol. 1989;42:213-215.
30. Garner A, Ball J. Quantitative observations on mineralised and unmineralised bone in chronic renal azotaemia and intestinal malabsorption syndrome. J Pathol Bacteriol. 1966;91:545-561.
31. Beck JS, Nordin BE. Histological assessment of osteoporosis by iliac crest biopsy. J Pathol Bacteriol. 1960;80:391-397.
32. Melsen F, Melsen B, Mosekilde L. An evaluation of the quantitative parameters applied in bone histology. ActaPathol Microbiol Scand [A]. 1978;86:63-69.
33. Moore RJ, Durbridge TC, Woods AE, Vernon- Roberts B. Variation in histomorphometric estimates across different sites of the iliac crest. J Clin Pathol. 1989;42:814-816.
34. Nadal E, Cervantes F, Rosinol L, Talarn C, Montserrat E. Hypercalcemia as the presenting feature of t-cell lymphoid blast crisis of ph-positive chronic myeloid leukemia. Leuk Lymphoma. 2001;41:203-206.
35. Solis-Herruzo JA, Castellano G, Fernandez I, Munoz R, Hawkins F. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol. 2000;33:812-817.
36. Kauppila M, Koskinen P, Pulkki K, et al. Interferon-alpha treatment decreases serum cross- linked C-terminal telopeptide of type I collagen in haematological diseases. Clin Lab Haematol. 2000;22:15-20.
37. Avnet S, Cenni E, Perut F, et al. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis. Int J Oncol. 2007;30:469-476.
38. Pérez Castrillón JL, Cano-del Pozo M, Sanz-Iz- quierdo S, Velayos-Jiménez J, Dib-Wobakin W. Bone mineral density in patients with multiple sclerosis: the effects of interferon [in Spanish]. Rev Neurol. 2003;36:901-903.
39. Yamaguchi A, Katagiri T, IkedaT, et al. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol. 1991;113:681-687.
40. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108:17-29.
41. Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science. 2005;308:1472-1477.
42. Debiais F, Lefevre G, Lemonnier J, et al. Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -p-catenin-independent signaling pathway. Exp Cell Res 2004;297:235-246
43. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-depen- dent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/ AKT. J Biol Chem. 2005;280:41342-41351.
44. Ghosh-Choudhury N, Abboud SL, Nishimura R, Celeste A, Mahimainathan L, ChoudhuryGG. Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription. J Biol Chem. 2002; 277:33361-33368.
45. Vinals F, Lopez-Rovira T, Rosa JL, Ventura F. Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett. 2002;510:99-104.
46. Fujita T, Azuma Y, Fukuyama R, et al. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol. 2004;166:85-95.
47. Fukuyama R, FujitaT, Azuma Y, et al. Statins inhibit osteoblast migration by inhibiting Rac-Akt signaling. Biochem Biophys Res Commun. 2004; 315:636-642.
48. Plattner R, Kadlec L, DeMali KA, KazlauskasA, PendergastAM. c-Abl is activated bygrowth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 1999;13: 2400-2411.
49. Plattner R, Koleske AJ, Kazlauskas A, Pendergast AM. Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol. 2004;24:2573-2583.
50. Pittenger MF, Mackay AM, Beck SC, et al. Multi- lineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
51. Summers SA, Whiteman EL, Cho H, Lipfert L Birnbaum MJ. Differentiation-dependent suppression of platelet-derived growth factor signaling in cultured adipocytes. J Biol Chem. 1999;274: 23858-23867.
52. Koellensperger E, von Heimburg D, Markowicz M, Pallua N. Human serum from platelet-poor plasma for the culture of primary human preadipocytes. Stem Cells. 2006;24:1218-1225.
53. Artemenko Y, Gagnon A, Aubin D, SoriskyA. Antiadipogenic effect of PDGF is reversed by PKC inhibition. J Cell Physiol. 2005;204:646-653.
54. Bost F, Aouadi M, Caron L, Binetruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie. 2005;87:51-56.
55. Aouadi M, Laurent K, Prot M, Le Marchand-Brustel Y, Binetruy B, Bost F. Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages. Diabetes. 2006;55:281-289.
56. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther. 2005;27:1-11.